基于IMRT的头颈部原发灶不明恶性肿瘤治疗:降低黏膜剂量与喉保留改善毒性的结局
回顾性分析58例头颈部原发灶不明鳞癌患者,接受IMRT治疗,黏膜剂量56 Gy组与≥60 Gy组复发无显著差异,但黏膜剂量和化疗类型与狭窄相关,56 Gy组PEG依赖中位时间缩短,喉保留方案改善狭窄和PEG使用结局。
要点
- 黏膜剂量56 Gy与≥60 Gy组复发无显著差异。
- 黏膜剂量和化疗类型与喉狭窄独立相关。
- 56 Gy组PEG依赖中位时间缩短,喉保留方案进一步改善结局。
核心结论
- 在这项单中心研究中,基于IMRT的56 Gy黏膜剂量显著改善吞咽毒性,喉保留IMRT可见额外获益。
研究设计与样本
- 回顾性分析2004年8月至2013年7月在Dana Farber癌症研究所接受IMRT治疗的58例头颈部原发灶不明鳞癌患者。
主要发现
- 黏膜剂量56 Gy组与≥60 Gy组之间任何复发均无显著差异。
- 多变量分析显示黏膜剂量和化疗类型与狭窄相关。
- 56 Gy组患者PEG依赖中位时间缩短。
- 喉保留方案与狭窄和PEG使用结局改善相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiation therapy for squamous cell cancer of the head and neck with unknown primary (head and neck CUP) has been associated with significant levels of swallowing toxicity. We examined the effect of changes in mucosal dose on development of laryngeal strictures and percutaneous endoscopic gastrostomy (PEG) dependence. METHODS: Retrospective analysis of 58 patients with head and neck CUP treated with intensity-modulated radiation therapy (IMRT) at the Dana Farber Cancer Institute from August 2004 through July 2013. RESULTS: There were no significant differences between any recurrences for groups treated to 56 versus ≥60 Gy to the mucosal surfaces. However, mucosal dose and chemotherapy type were associated with stricture on multivariable analysis; median PEG dependence was decreased for patients treated to 56 Gy. A larynx-sparing approach was associated with improved outcomes for strictures and PEG use. CONCLUSION: In this single institution study, a 56 Gy IMRT-based mucosal dose demonstrated significant improvements in swallowing toxicity. Additional benefit was seen with larynx-sparing IMRT.
引用
- LaVigne AW, Margalit DN, Rawal B, et al. IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019. PMID: 30620435. doi:10.1002/hed.25531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。